Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sonelokimab - MoonLake Immunotherapeutics

Drug Profile

Sonelokimab - MoonLake Immunotherapeutics

Alternative Names: ALX 0761; Anti-IL-17A/F Nanobody; M 1095; MSB-0010841; Nanobody® IL-17 A/F inhibitor; Sonelokinab

Latest Information Update: 13 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ablynx
  • Developer Avillion; MoonLake Immunotherapeutics
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Single-domain antibodies; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hidradenitis suppurativa
  • Phase II Psoriasis; Psoriatic arthritis
  • Phase I Ankylosing spondylitis

Most Recent Events

  • 10 Jun 2024 MoonLake Immunotherapeutics receive positive feedback from both FDA and EMA for the phase III program in psoriatic arthritis
  • 13 May 2024 Phase-III clinical trials in Hidradenitis suppurativa in USA (SC) (NCT06411379)
  • 13 May 2024 MoonLake Immunotherapeutics plans a phase III trial for Hidradenitis Suppurativa (In adults) in May 2024 (SC) (NCT06411899)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top